Click Holdings Limited (NASDAQ:CLIK) Sees Significant Decline in Short Interest

Click Holdings Limited (NASDAQ:CLIK) saw a large decline in short interest in the month of May. As of May 29th, there was short interest totaling 50,211 shares, a decline of 48.6% from the May 14th total of 97,673 shares. Approximately 4.4% of the shares of the company are short sold. Based on an average daily trading volume, of 1,195,878 shares, the short-interest ratio is currently 0.0 days.

Click Stock Performance

Shares of CLIK traded down $0.01 on Monday, reaching $1.57. 218,631 shares of the stock traded hands, compared to its average volume of 1,756,678. Click has a 12 month low of $1.32 and a 12 month high of $15.90. The stock’s 50-day moving average price is $2.12 and its 200-day moving average price is $3.58.

Click (NASDAQ:CLIK) last released its quarterly earnings data on Monday, May 11th. The company reported $0.10 earnings per share (EPS) for the quarter. The firm had revenue of $3.79 million for the quarter.

Institutional Trading of Click

A hedge fund recently bought a new stake in Click stock. Renaissance Technologies LLC purchased a new stake in Click Holdings Limited (NASDAQ:CLIK) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 14,200 shares of the company’s stock, valued at approximately $25,000. Renaissance Technologies LLC owned approximately 1.23% of Click at the end of the most recent reporting period.

Analysts Set New Price Targets

Several research analysts have commented on CLIK shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Click in a research report on Friday, March 27th. Wall Street Zen raised Click to a “hold” rating in a research report on Saturday. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Click presently has a consensus rating of “Sell”.

About Click

Click Therapeutics, Inc (NASDAQ: CLIK) is a clinical-stage digital therapeutics company developing software-based treatments for neurological, psychiatric and chronic diseases. Its platform delivers prescription digital therapies via mobile and web applications, combining evidence-based cognitive behavioral interventions, digital monitoring tools and patient engagement techniques. Click’s approach is designed to complement or extend traditional pharmacological and behavioral treatments for conditions such as major depressive disorder, insomnia and tobacco use disorder.

Founded in 2014, Click has progressed multiple programs through randomized controlled trials and regulatory review.